Sign inJoin waitlistJoin the waitlist

Jacqueline Kraveka

Professor, Department of Pediatrics · Medical University of South Carolina College of Medicine

Credentials: · · ·

History

Medical University of South Carolina College of Medicine
Present

Pediatric Hematology Oncology
Medical University of South Carolina College of Medicine
1997–2000
Pediatrics
Nicklaus Children's Hospital
1995–1997
Nova Southeastern University College of Osteopathic Medicine
1990–1994

Research

Effect of Tandem Autologous Stem Cell Transplant vs Single Transplant on Event-Free Survival in Patients With High-Risk Neuroblastoma: A Randomized Clinical Trial
JAMA · 2019 · 300 citations
Updates in Diagnosis, Management, and Treatment of Neuroblastoma
Review · Radiographics · 2018 · 206 citations
Involvement of dihydroceramide desaturase in cell cycle progression in human neuroblastoma cells
Journal of Biological Chemistry · 2007 · First of 8 authors · Corresponding · 153 citations

William Ferguson
11 papers
Deanna Mitchell
10 papers
DE
Don Eslin
10 papers
William Roberts
10 papers
Yusuf Hannun
9 papers
Giselle Sholler
8 papers
LO
Lina Obeid
8 papers
R Wada
8 papers
Valerie Brown
7 papers
Javier Oesterheld
6 papers
JR
Jawhar Rawwas
6 papers
MI
Michael Isakoff
6 papers

Grants

Role of Ceramide in Human Neuroblastoma Differentiation
National Cancer Institute · K01
Contact PI · $684.7K · Medical University of South Carolina
2003–2008

Clinical trials

Comparison of Two Combination Chemotherapy Regimens With Either Vincristine or Vinblastine in Treating Patients With Advanced Anaplastic Large Cell Lymphoma
Study chair · Completed · Phase 3
Children's Oncology Group
2003–2014
The CATSINDO Trial - Clinical and Translational Study in Newly Diagnosed Osteosarcoma
Site PI · Not yet recruiting · Phase 2
Wake Forest University Health Sciences
2026–2028
Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma
Site PI · Recruiting · Phase 3
National Cancer Institute (NCI)
2024–2029
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
Site PI · Recruiting · Phase 3
National Cancer Institute (NCI)
2023–2031